Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jan 15;8(1):e00534.
doi: 10.14309/crj.0000000000000534. eCollection 2021 Jan.

Intragastric Balloon Improves Steatohepatitis and Fibrosis

Elissa Lin  1 , Xiaoyan Huang  2 , Zhiheng Pei  2 , Jonathan Gross  3 , Violeta Popov  4
Affiliations
Case Reports

Intragastric Balloon Improves Steatohepatitis and Fibrosis

Elissa Lin et al. ACG Case Rep J. .

Abstract

Obesity is a major risk factor for nonalcoholic steatohepatitis (NASH). Although weight loss has been shown to reverse histologic features of NASH, lifestyle intervention alone is often challenging and unfeasible. In this case report, we discuss the effects of intragastric balloon (IGB) therapy on steatosis, fibrosis, and portal pressures. We also demonstrate that improvement in histologic features persist at least 6 months after IGB removal. Although there are little data thus far to support IGB therapy in the treatment of NASH, our case provides evidence of the potential benefit of IGB on improving metabolic parameters and markers of liver fibrosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Histopathologic changes in liver biopsy (A–C) before and (D–F) after treatment. (A and D) Masson trichrome staining, 2× magnification; (B and E) Masson trichrome staining 40× magnification; (C and F) H&E, 10× magnification.
See this image and copyright information in PMC

References

    1. Cotter TG, Rinella M, NAFLD 2020: The state of the disease, Gastroenterology. 2020;158(7):1851–64. - PubMed
    1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. - PubMed
    1. Popov VB, Ou A, Schulman AR, Thompson CC. The impact of intragastric balloons on obesity-related co-morbidities: A systematic review and meta-analysis. Am J Gastroenterol. 2017;112(3):429–39. - PubMed
    1. Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic fatty liver disease and insulin resistance: New insights and potential new treatments. Nutrients. 2017;9(4):387. - PMC - PubMed
    1. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005;172(7):899–905. - PMC - PubMed

Publication types